ArticleCureus2026
Comparison of Sugammadex and Neostigmine for Reversal of Vecuronium-Induced Neuromuscular Blockade in Pediatric Patients: A Prospective Randomized Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective Neuromuscular blocking agents (NMBAs) used during general anesthesia require effective reversal to prevent residual paralysis. Neostigmine, the conventional reversal agent, is associated with slower recovery and muscarinic side effects. Sugammadex selectively encapsulates amino-steroidal NMBAs, providing rapid and predictable reversal. This study compared the efficacy, safety, and recovery profile of sugammadex and neostigmine for reversal of vecuronium-induced neuromuscular blockade in children. Methods In this prospective, randomized, double-blind trial, 100 children aged two to 12 years (American Society of Anesthesiologists (ASA) I-III) undergoing elective surgery requiring general anesthesia were randomized to receive sugammadex (2 mg/kg) or neostigmine (50 mcg/kg) with glycopyrrolate (10 mcg/kg). Neuromuscular function was monitored using train-of-four (TOF) stimulation. The primary outcome was time to achieve TOF ratios of ≥0.9 and 1.0 after reversal. Secondary outcomes included residual neuromuscular blockade, functional respiratory recovery assessed by tidal volume, hemodynamic adverse events, and respiratory complications. Results Demographic and intraoperative characteristics were comparable between groups. The median time (±IQR) to achieve TOF ≥0.9 and 1.0 was significantly shorter with Sugammadex than with Neostigmine [70(65-108) vs 252(240-280) and 85.5(75-142) vs 272(255-304) seconds, respectively, p = 0.001]. Heart rate was significantly higher following reversal with neostigmine and glycopyrrolate than with sugammadex, with the difference peaking at five minutes and progressively narrowing thereafter, but remaining significant for up to 1.5 hours after arrival in the post-anesthesia care unit. Tidal volume increased more rapidly with sugammadex than neostigmine after reversal, although this exploratory secondary outcome does not establish a causal relationship. Conclusions Sugammadex provided significantly faster and more reliable reversal of vecuronium-induced neuromuscular blockade in children aged two to 12 years, compared to neostigmine (as shown by neuromuscular monitoring), with less tachycardia following reversal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.